 |
| Tissue Plasminogen Activator Market |
Tissue plasminogen activator (tPA) is a thrombolytic drug used to treat myocardial infarction and ischemic stroke. It works by breaking down blood clots and restoring blood flow to blocked arteries. tPA has advantages over other thrombolytic drugs as it provides faster recovery, reduces disability, and improves quality of life. The increasing risk of cardiovascular diseases due to changing lifestyle and aging population has fueled the demand for tPA globally.
The global Tissue Plasminogen Activator Market is estimated to be valued at US$ 2.58 Bn in 2023 and is expected to
exhibit a CAGR of 6.1% over the
forecast period 2023 to 2030, as highlighted in a new report published by
Coherent Market Insights.
Market key trends:
The rising prevalence of cardiovascular diseases is one of the key drivers of
the tissue plasminogen activator market. Cardiovascular diseases have become
one of the leading causes of death and disability worldwide. According to the
World Health Organization, cardiovascular diseases accounted for over 17.9
million deaths in 2019, representing 32% of all global deaths. The increasing
risk factors such as sedentary lifestyle, obesity, and consumption of tobacco
and alcohol have significantly contributed to the growing burden of cardiovascular
diseases. As tissue plasminogen activator is primarily used for the treatment
of heart attacks and strokes, the rising incidences of such diseases have
accelerated the demand for tPA drugs over the last few years.
Segment Analysis
The global tissue plasminogen activator market is segmented based on
application into thrombotic disease, pulmonary embolism, acute myocardial
infarction, ischemic stroke, and others. The ischemic stroke sub segment
accounts for the largest share in the market currently due to the increasing
incidence of ischemic strokes among the elderly population globally. The
thrombolysis using tissue plasminogen activator is one of the standard
treatments for ischemic strokes, which is driving the growth of this sub
segment.
Key Takeaways
The global Tissue
Plasminogen Activator Market Share is expected to witness high growth
over the forecast period of 2023 to 2030. The global Tissue Plasminogen
Activator Market is estimated to be valued at US$ 2.58 Bn in 2023 and is
expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030.
Regional
analysis indicates North America will continue dominating the market due to
supportive government policies and reimbursement structure for treatments
related to cardiovascular diseases and strokes. Additionally, the rising
prevalence of heart attacks and strokes mainly in the US and Canada is
supporting market growth.
Key players operating in the tissue plasminogen activator market are Boehringer
Ingelheim, Emcure Pharmaceuticals, Genentech, and Merck & Co. Genentech
holds a significant share in the market owing to its popular brand Activase
indicated for ischemic stroke and myocardial infarction. The firm has a strong
geographical presence and brand recognition.
0 Comments